Group One Trading’s Emergent Biosolutions EBS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-18,149
| Closed | -$152K | – | 7804 |
|
|
2026
Q1 | $151K | Buy |
18,149
+11,109
| +158% | +$115K | ﹤0.01% | 4355 |
|
|
2025
Q4 | $87K | Sell |
7,040
-89,240
| -93% | -$956K | ﹤0.01% | 5115 |
|
|
2025
Q3 | $849K | Buy |
96,280
+13,470
| +16% | +$105K | ﹤0.01% | 3197 |
|
|
2025
Q2 | $528K | Buy |
+82,810
| New | +$474K | ﹤0.01% | 3361 |
|
|
2025
Q1 | – | Sell |
-37,609
| Closed | -$311K | – | 7780 |
|
|
2024
Q4 | $360K | Sell |
37,609
-8,000
| -18% | -$73.4K | ﹤0.01% | 3441 |
|
|
2024
Q3 | $381K | Buy |
+45,609
| New | +$415K | ﹤0.01% | 3066 |
|
|
2024
Q1 | – | Sell |
-273,774
| Closed | -$617K | – | 7242 |
|
|
2023
Q4 | $657K | Buy |
273,774
+83,133
| +44% | +$195K | ﹤0.01% | 2840 |
|
|
2023
Q3 | $648K | Buy |
190,641
+188,920
| +10,977% | +$1.05M | ﹤0.01% | 2664 |
|
|
2023
Q2 | $12.6K | Buy |
1,721
+1,389
| +418% | +$12.9K | ﹤0.01% | 6263 |
|
|
2023
Q1 | $3.44K | Sell |
332
-10,629
| -97% | -$128K | ﹤0.01% | 6441 |
|
|
2022
Q4 | $129K | Buy |
10,961
+8,844
| +418% | +$137K | ﹤0.01% | 4211 |
|
|
2022
Q3 | $44K | Sell |
2,117
-6,200
| -75% | -$173K | ﹤0.01% | 5500 |
|
|
2022
Q2 | $258K | Buy |
8,317
+3,414
| +70% | +$117K | ﹤0.01% | 4051 |
|
|
2022
Q1 | $201K | Sell |
4,903
-6,211
| -56% | -$274K | ﹤0.01% | 4795 |
|
|
2021
Q4 | $483K | Sell |
11,114
-8,459
| -43% | -$383K | ﹤0.01% | 4173 |
|
|
2021
Q3 | $980K | Buy |
19,573
+3,300
| +20% | +$200K | ﹤0.01% | 3438 |
|
|
2021
Q2 | $1.02M | Buy |
16,273
+12,005
| +281% | +$771K | ﹤0.01% | 3389 |
|
|
2021
Q1 | $397K | Sell |
4,268
-10,386
| -71% | -$1.06M | ﹤0.01% | 4302 |
|
|
2020
Q4 | $1.31M | Sell |
14,654
-12,874
| -47% | -$1.18M | ﹤0.01% | 2402 |
|
|
2020
Q3 | $2.84M | Buy |
+27,528
| New | +$2.97M | 0.01% | 1313 |
|
|
2018
Q4 | – | Sell |
-200
| Closed | -$13K | – | 4981 |
|
|
2018
Q3 | $13K | Buy |
+200
| New | +$11.7K | ﹤0.01% | 4566 |
|
|
2017
Q3 | – | Sell |
-2,500
| Closed | -$90.5K | – | 4896 |
|
|
2017
Q2 | $85K | Buy |
+2,500
| New | +$77.2K | ﹤0.01% | 3208 |
|
|
2017
Q1 | – | Sell |
-1,400
| Closed | -$46K | – | 4709 |
|
|
2016
Q4 | $46K | Buy |
1,400
+1,300
| +1,300% | +$39K | ﹤0.01% | 3304 |
|
|
2016
Q3 | $3K | Sell |
100
-1,100
| -92% | -$32K | ﹤0.01% | 4295 |
|
|
2016
Q2 | $34K | Buy |
+1,200
| New | +$47K | ﹤0.01% | 3538 |
|
Other funds holding EBS
OHA
Group One Trading's EBS Position: Q2 2026 in Review
Group One Trading sold out of Emergent Biosolutions (EBS) in Q2 2026, closing a stake of 18,149 shares — an estimated $152K sold.
Group One Trading first reported a position in EBS in Q2 2016 and held it in 25 quarters. The position peaked at $2.84M in Q3 2020. 195 funds tracked by Wall St. Rank hold EBS as of Q2 2026.
- Group One Trading reported no remaining Emergent Biosolutions position as of Q2 2026 after selling out during the quarter.
- Group One Trading sold 18,149 Emergent Biosolutions shares in Q2 2026, an estimated $152K.
- Group One Trading first reported a position in Emergent Biosolutions in Q2 2016 and held it in 25 quarters.
- Group One Trading's Emergent Biosolutions position peaked at $2.84M in Q3 2020.
- 195 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.
Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.